Enfortumab Vedotin in Metastatic Urothelial Carcinoma: Survival and Safety in a European Multicenter Real-world Patient Cohort

Enfortumab Vedotin in Metastatic Urothelial Carcinoma: Survival and Safety in a European Multicenter Real-world Patient Cohort

Background: Treatment options for patients with urothelial cancer (UC) refractory to platinum and immunotherapy are limited and survival is short. Enfortumab vedotin (EV) is a monoclonal anti-NECTIN4 antibody conjugated to monomethyl auristatin. It was recently approved because of superior survival...

Full description

Bibliographic Details
Main Authors: Stefanie Zschäbitz, Nadine Biernath, Thomas Hilser, Alexander Höllein, Friedemann Zengerling, Jozefina Cascucelli, Pia Paffenholz, Daniel Seidl, Christoph Lutz, Katrin Schlack, Dorothea Kingreen, Niklas Klümper, Philipp Ivanyi, Gunhild von Amsberg, Hendrik Heers, Florian Roghmann, Robert L. Tauber, Richard Cathomas, Luisa Hofer, Günter Niegisch, Melanie Klee, Roland Ehrenberg, Andreas Hassler, Boris A. Hadaschik, Viktor Grünwald, Christopher Darr
Format: Article
Language:English
Published: Elsevier 2023-07-01
Series:European Urology Open Science
Subjects:
Enfortumab vedotin
Urothelial cancer
Real-world data
NECTIN4
Online Access:http://www.sciencedirect.com/science/article/pii/S2666168323002185

Internet

http://www.sciencedirect.com/science/article/pii/S2666168323002185

Similar Items